guselkumab vs picankibart

NCT02203032 · Phase 3 · completed

In patients who had not responded well enough to ustekinumab, switching to guselkumab under randomized, blinded conditions produced significantly more visits with clear or almost-clear skin than staying on ustekinumab, a clinically meaningful and statistically significant result in a study designed and blinded to make that comparison fairly.

NCT05645627 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 500 participants. The sponsor reports that picankibart met its co-primary endpoints, with 80.3% of picankibart patients reaching PASI90 (at least 90% skin clearance) at week 16, compared with 2.0% of placebo patients, a highly significant difference.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

QUASAR/GALAXI · Phase 3 · completed

Only IL-23i to beat ustekinumab head-to-head on endoscopy in a registrational trial — strong differentiator.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

NCT05377580 · Phase 2 · completed

This trial randomized 150 patients with moderate-to-severe ulcerative colitis to picankibart at several doses or placebo under double-blind conditions, with clinical remission at Week 12 as the primary measure. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.